Skip to main content
TSHA logo

TSHA · Taysha Gene Therapies, Inc. · Executive Compensation

Track TSHA — free
$4.74 -0.13 (-2.67%) At close · Oct 1
Market Cap
$1.52B
Shares
325.83M
Volume · Oct 1 3.85M Avg daily vol (3M) 3.16M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Sean Nolan $4,099,065
Kamran Alam $2,146,964
Sukumar Nagendran $2,092,890
Fiscal 2024
Executive Total
Sean Nolan $4,727,861
Sukumar Nagendran $3,601,660
Kamran Alam $2,518,777
Fiscal 2023
Executive Total
Sean Nolan $1,522,515
Sukumar Nagendran $1,248,120
Kamran Alam $975,401
Fiscal 2022
Executive Total
Sean Nolan $1,899,276
Sukumar Nagendran $1,363,545
Kamran Alam $1,201,823

Executive changes

Person Change Filed
Kathleen Reape Resigned 2023-11-01
Sean Stalfort Appointed 2023-06-22
Paul B. Manning Resigned 2023-06-22
Kathleen Reape Resigned 2023-04-27
Sukumar Nagendran Appointed 2022-12-22
Sean Nolan Appointed 2022-12-22
RA Session II Resigned 2022-12-22
Key facts CIK 1806310 CUSIP 877619106 13F (30d) 5 filings 5 filers Visit website Investor relations